Your patients are certain to have questions and concerns about CML (chronic myeloid leukaemia), GIST (gastrointestinal stromal tumour), and Glivec^® (imatinib).

Use the GIPAP section to learn more about how the Glivec International Patient Assistance Program (GIPAP) can enhance patient access to Glivec. GIPAP has been expanded to 80 countries, and has reached more than 27,108 patients.

Our patient care materials such as Common Patient Questions will help your patients better understand their condition and treatment with Glivec. Frequently asked questions provide answers to offer pertinent information about treatment options and understanding diagnosis and treatment of CML in CML FAQs and of GIST in GIST FAQs.